Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)

BIOKIN's SI-B036 Bispecific Antibody Injection Receives Clinical Trial Approval for Advanced Solid Tumors

Shoulder Innovations Reports First Quarter 2026 Financial Results And Raises Full Year Outlook

Shoulder Innovations Inc reports results for the quarter ended March 31 - Earnings Summary

Shoulder Innovations Q1 EPS $(0.41) Misses $(0.40) Estimate, Sales $16.708M Beat $14.536M Estimate

Shoulder Innovations Q1 operating loss widens to $8.98 million; revenue rises 65% to $16.7 million

Shoulder Innovations: Expects Net Revenue for the Full Year 2026 to Be in the Range of $65 Million to $68 Million

Shoulder Innovations Inc FY2026 REV View $64.1 Mln -- Lseg Ibes Data

Shoulder Innovations Inc Q1 EBIT USD -8.976 Million

Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN)

SI-BONE Earnings Call Signals Profitable Growth Momentum

SI-BONE Raises 2026 Revenue Forecast to $230-$233 Million

SI-BONE Price Target Cut to $18.00/Share From $20.00 by Truist Securities

TD Cowen Reaffirms Their Buy Rating on SI-Bone (SIBN)

Truist Lowers Price Target on SI-BONE to $18 From $20, Keeps Buy Rating Rating

Shoulder Innovations Inc expected to post a loss of 41 cents a share - Earnings Preview

SI-BONE Q1 Loss Narrows, Revenue Rises; Raises 2026 Revenue Outlook

SI-Bone reports Q1 EPS (10c), consensus (19c)